Crinetics Pharmaceuticals, Inc. (CRNX)
84.95
0.00 (0.00%)
Inactive · Last trade price on Aug 31, 2026
Crinetics Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 42.16 | 7.7 | 1.04 | 4.01 | 4.74 | 1.08 | |
Revenue Growth | 2928.45% | 640.71% | -74.11% | -15.28% | 339.43% | 1418.31% |
Cost of Revenue | 376.88 | 333.13 | 240.16 | 168.53 | 130.23 | 84.26 |
Gross Profit | -334.72 | -325.44 | -239.12 | -164.51 | -125.49 | -83.18 |
Selling, General & Admin | 214.37 | 191.33 | 99.74 | 58.09 | 42.39 | 24.53 |
Operating Expenses | 214.37 | 191.33 | 99.74 | 58.09 | 42.39 | 24.53 |
Operating Income | -549.09 | -516.77 | -338.85 | -222.61 | -167.88 | -107.7 |
Interest & Investment Income | 48.39 | 51.99 | 41.44 | 13.44 | 4.32 | 0.16 |
Earnings From Equity Investments | - | - | -0.47 | -5.2 | -1.01 | - |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0.11 |
Other Non Operating Income (Expenses) | -0.73 | -0.36 | -0.52 | -0.16 | 0.66 | 0.01 |
Pretax Income | -501.43 | -465.14 | -298.41 | -214.53 | -163.92 | -107.64 |
Income Tax Expense | 0.18 | 0.18 | - | - | - | - |
Net Income | -501.61 | -465.32 | -298.41 | -214.53 | -163.92 | -107.64 |
Net Income to Common | -501.61 | -465.32 | -298.41 | -214.53 | -163.92 | -107.64 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 100 | 94 | 81 | 58 | 52 | 38 |
Shares Outstanding (Diluted) | 100 | 94 | 81 | 58 | 52 | 38 |
Shares Change | 11.25% | 16.43% | 39.11% | 11.71% | 35.24% | 26.24% |
EPS (Basic) | -5.03 | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 |
EPS (Diluted) | -5.03 | -4.95 | -3.69 | -3.69 | -3.15 | -2.80 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -425.18 | -383.68 | -234.04 | -173.29 | -116.86 | -89.02 |
Free Cash Flow Per Share | -4.26 | -4.08 | -2.90 | -2.98 | -2.25 | -2.32 |
Operating Margin | -1302.52% | -6714.77% | -32613.47% | -5547.17% | -3544.06% | -9990.91% |
Profit Margin | -1189.88% | -6046.22% | -28720.69% | -5345.85% | -3460.38% | -9985.25% |
Free Cash Flow Margin | -1008.58% | -4985.50% | -22525.31% | -4318.12% | -2466.98% | -8258.26% |
EBITDA | -544.85 | -512.88 | -336.07 | -221.51 | -166.9 | -106.78 |
D&A For EBITDA | 4.24 | 3.89 | 2.79 | 1.1 | 0.98 | 0.92 |
EBIT | -549.09 | -516.77 | -338.85 | -222.61 | -167.88 | -107.7 |
Revenue as Reported | 42.16 | 7.7 | 1.04 | 4.01 | - | - |
Advertising Expenses | - | 16.9 | - | - | - | - |